11/5/19: The saga of Mylan and the EpiPen gained national attention when the cost of the drug skyrocketed. The SEC’s interest in the issues surrounding the EpiPen and its manufacturer involved Medicaid fraud...
The SEC complaint alleged that Mylan had overcharged Medicaid by classifying the drug as “generic,” thereby paying lower rebates to the government under the Medicaid Drug Rebate Program than if the EpiPen had been classified as a “branded” drug. According to the SEC, Mylan had been informed about the misclassification as early as October 2014, finally culminating in Mylan agreeing to pay #30 million to settle SEC charges....